Previous studies showed a reduced incretin effect in patients with type 2 diabetes but a robust response to exogenous GLP-1. The primary goal of this study was to determine whether endogenous GLP ...
“Whether consumers are using GLP-1 medications for weight management or are reducing sugar intake as part of their overall ...
an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1 ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Hosted on MSN26d
A new path to recovery: Scientists uncover key brain circuit in the fight against cocaine use disorderMore information: Riley Merkel et al, An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking, Science Advances (2025).
Reference: Merkel R, Hernandez NS, Weir V, et al. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Sci Adv.
Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies ...
In a post hoc analysis of patients from the phase 1b clinical trial, IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels and, in preclinical testing ...
In a post hoc analysis of patients from the phase 1b clinical trial, IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels and, in preclinical testing ...
New Data Suggests that IMU-856 Could Be a Potential Oral treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback